Celldex Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-283.65	-258.76	-157.86	-141.43	-112.33	-70.51
Depreciation & Amortization	3.37	3.38	3.18	3.01	2.9	3.07
Stock-Based Compensation	35.42	36.22	34.24	23.89	15.61	8.95
Other Adjustments	-4.21	-5.84	-15.73	-6.22	-6.02	-1.37
Change in Receivables	0.83	-1.32	1.93	-2.28	-0.18	1.57
Changes in Accounts Payable	19.46	11.03	11.63	9.38	3.12	3.65
Changes in Other Operating Activities	6.61	4.34	-35.16	6.36	-6.85	-6.28
Operating Cash Flow	-222.16	-210.95	-157.78	-107.29	-103.73	-60.91
Capital Expenditures	-4.09	-2.71	-1.92	-1.82	-1.83	-1.25
Sale of Property, Plant & Equipment	-	-	-	-	0.07	0.03
Purchases of Investments	-292.29	-384.5	-789.92	-424.56	-188.97	-389.88
Proceeds from Sale of Investments	534.62	596.29	501.71	320.6	280.67	174.95
Investing Cash Flow	238.24	209.07	-290.13	-105.78	89.94	-216.16
Issuance of Common Stock	2.51	2.39	441.45	218.46	4.08	272.37
Net Common Stock Issued (Repurchased)	2.51	2.39	441.45	218.46	4.08	272.37
Financing Cash Flow	2.51	2.39	441.45	218.46	4.08	272.37
Net Cash Flow	18.59	0.52	-6.46	5.39	-9.71	-4.69
Free Cash Flow	-226.25	-213.66	-159.7	-109.11	-105.56	-62.16
FCF Margin	-26125.80%	-13829.10%	-2274.89%	-1584.97%	-4478.57%	-1336.44%
Free Cash Flow Per Share	-3.40	-3.22	-2.48	-2.25	-2.25	-1.45
Levered Free Cash Flow	-258.3	-242.72	-180.13	-124.5	-114.98	-71.32
Unlevered Free Cash Flow	-283.72	-271.33	-217.35	-137.61	-117.89	-71.82

SEC Filings: 10-K · 10-Q